Predicted long-term persistence of pertussis antibodies in adolescents after an adolescent and adult formulation combined tetanus, diphtheria, and 5-component acellular pertussis vaccine, based on mathematical modeling and 5-year observed data

Vaccine

Volumn 26, Issue 31, 2008, Pages 3903-3908

  Bailleux, F ^a   Coudeville, L ^a   Kolenc Saban, A ^b   Bevilacqua, J ^b   Barreto, L ^b   Andre P ^a  

^a SANOFI PASTEUR   (France)

^b Sanofi Pasteur   (Canada)

Author keywords

Adolescents; Booster administration; Linear regression; Pertussis antibodies decay

Indexed keywords

DIPHTHERIA PERTUSSIS TETANUS VACCINE; FIMBRIA PROTEIN; HEMAGGLUTININ; HEPATITIS B VACCINE; PERTACTIN;

ADOLESCENT; ANTIBODY BLOOD LEVEL; ANTIBODY TITER; ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; FIMBRIA; HUMAN; IMMUNOGENICITY; MAJOR CLINICAL STUDY; MATHEMATICAL MODEL; PERTUSSIS; PRIORITY JOURNAL; SCHOOL CHILD; SEROLOGY; VACCINATION;

ADHESINS, BACTERIAL; ADOLESCENT; ADULT; ANTIBODIES, BACTERIAL; BACTERIAL OUTER MEMBRANE PROTEINS; CHILD; DIPHTHERIA-TETANUS-PERTUSSIS VACCINE; FIMBRIAE, BACTERIAL; HUMANS; IMMUNIZATION, SECONDARY; MODELS, THEORETICAL; TIME FACTORS; TOXOIDS; VIRULENCE FACTORS, BORDETELLA;

EID: 46149126366     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2008.04.089     Document Type: Article

References (33)

1. Edwards K.M. Overview of pertussis: focus on epidemiology, sources of infection, and long term protection after infant vaccination. Pediatr Infect Dis J 24 Suppl. 6 (2005) S104-S108
2. Mattoo S., and Cherry J.D. Molecular pathogenesis, epidemiology, and clinical manifestations of respiratory infections due to Bordetella pertussis and other Bordetella subspecies. Clin Microbiol Rev 18 2 (2005) 326-382
3. Tan T., Trindade E., and Skowronski D. Epidemiology of pertussis. Pediatr Infect Dis J 24 (2005) S10-S18
4. Centers for Disease Control and Prevention. Summary of notifiable diseases, United States, 2003. Morb Mortal Wkly Rep 52 (2003) 1-85
5. Centers for Disease Control and Prevention. Notifiable diseases/deaths in selected cities, weekly information. Morb Mortal Wkly Rep 53 52 (2005) 1213-1221
6. Bisgard K.M., Pascual F.B., Ehresmann K.R., Miller C.A., Cianfrini C., Jennings C.E., et al. Infant pertussis: who was the source?. Pediatr Infect Dis J 23 (2004) 985-989
7. Gonik B., Puder K.S., Gonik N., and Kruger M. Seroprevalence of Bordetella pertussis antibodies in mothers and their newborn infants. Infect Dis Obstet Gynecol 13 2 (2005) 59-61
8. Schellekens J., von Konig C.H., and Gardner P. Pertussis sources of infection and routes of transmission in the vaccination era. Pediatr Infect Dis J 24 Suppl. 5 (2005) S19-S24
9. Cherry J.D. The epidemiology of pertussis: a comparison of the epidemiology of the disease pertussis with the epidemiology of Bordetella pertussis infection. Pediatrics 115 5 (2005) 1422-1427
10. Centers for Disease Control and Prevention (CDC). Recommended childhood and adolescent immunization schedule-United State, January-June 2004. Morb Mortal Wkly Rep 53 1 (2004) Q1-Q4
11. McIntyre P.B., Turnbull F.M., Egan A.M., Burgess M.A., Wolter J.M., and Schuerman L.M. High levels of antibody in adults three years after vaccination with a reduced antigen content diphtheria-tetanus-acellular pertussis vaccine. Vaccine 23 (2004) 380-385
12. Edelman K.J., He Q., Makinen J.P., Haanpera M.S., Nguyen Tran Minh N., Schuerman L., et al. Pertussis-specific cell-mediated and humoral immunity in adolescents 3 years after booster immunization with acellular pertussis vaccine. Clin Infect Dis 39 (2004) 179-185
13. Le T., Cherry J.D., Chang S.J., Knoll M.D., Lee M.L., Barenkamp S., et al. APERT Study. Immune responses and antibody decay after immunization of adolescents and adults with an acellular pertussis vaccine: the APERT Study. J Infect Dis 190 (2004) 535-544
14. Edelman K., He Q., Makinen J., Sahlberg A., Haanpera M., Schuerman L., et al. Immunity to pertussis 5 years after booster immunization during adolescence. Clin Infect Dis 44 (2007) 1271-1277
15. Storaeter J., Hallander H., Gustafsson L., and Olin P. Level of anti-pertussis antibodies related to protection after household exposure to Bordetella pertussis. Vaccine 16 (1998) 1907-1916
16. Giuliano M., Mastrantonio P., Giammanco A., Bottone M., Piscitelli A., Di Tommaso S., et al. Antibody kinetics and long term sero-prevalence in the Italian clinical trial of acellular pertussis vaccines. Dev Biol Stand 89 (1997) 275-278
17. Bell F., Martin A., Blondeau C., Thornton C., Chaplais J., and Finn A. Combined diphtheria, tetanus, pertussis, and Haemophilus influenzae type b vaccines for primary immunisation. Arch Dis Child 75 (1996) 298-303
18. Tomoda T., Ogura H., and Kurashige T. Immune responses to Bordetella pertussis infection and vaccination. J Infect Dis 163 (1991) 559-563
19. Isacson J., Trollfors B., Hedvall G., Taranger J., and Zackrisson G. Response and decline of serum IgG antibodies to pertussis toxin, filamentous hemagglutinin and pertactin in children with pertussis. Scand J Infect Dis 27 (1995) 273-277
20. de Melker H.E., Versteegh F.G., Conyn-Van Spaendonck M.A., Elvers L.H., Berbers G.A., van Der Zee A., et al. Specificity and sensitivity of high levels of immunoglobulin G antibodies against pertussis toxin in a single serum sample for diagnosis of infection with Bordetella pertussis. J Clin Microbiol 38 (2000) 800-806
21. Heininger U., Cherry J.D., and Stehr K. Serologic response and antibody-titer decay in adults with pertussis. Clin Infect Dis 38 (2004) 591-594
22. Edwards K.M., Decker M.D., Graham B.S., Mezzatesta J., Scott J., and Hackell J. Adult immunization with acellular pertussis vaccine. JAMA 269 (1993) 93-94
23. Keitel W.A., Muenz L.R., Decker M.D., Englund J.A., Mink C.M., Blumberg D.A., et al. A randomized clinical trial of acellular pertussis vaccines in healthy adults: dose-response comparisons of 5 vaccines and implications for booster immunization. J Infect Dis 180 (1999) 397-403
24. Barreto L., Guasparini R., Meekison W., Noya F., Young L., and Mills E. Humoral immunity 5 years after booster immunization with an adolescent and adult formulation combined tetanus, diphtheria, and 5-component acellular pertussis vaccine. Vaccine 25 (2007) 8172-8179
25. Halperin S.A., Smith B., Russell M., Hasselback P., Guasparini R., Skowronski D., et al. Adult formulation of a five component acellular pertussis vaccine combined with diphtheria and tetanus toxoids and inactivated poliovirus vaccine is safe and immunogenic in adolescents and adults. Pediatr Infect Dis J 19 4 (2000) 276-283
26. Cherry J.D., Gornbein J., Heininger U., and Stehr K. A search for serologic correlates of immunity to Bordetella pertussis cough illnesses. Vaccine 16 (1998) 1901-1906
27. Teunis P.F., van der Heijden O.G., de Melker H.E., Schellekens J.F., Versteegh F.G., and Kretzschmar M.E. Kinetics of the IgG antibody response to pertussis toxin after infection with B. pertussis. Epidemiol Infect 129 3 (2002) 479-489
28. Tiru M., Hallander H.O., Gustafsson L., Storsaeter J., and Olin P. Diphtheria antitoxin response to DTP vaccines used in Swedish pertussis vaccine trials, persistence and projection for timing of booster. Vaccine 18 (2000) 2295-2306
29. Amanna I., Carlson N., and Slifka M. Duration of humoral immunity to common viral and vaccine antigens. N Engl J Med 357 (2007) 1903-1915
30. Cheuvart B., Burgess M., Zepp F., Mertsola J., Wolter J., and Schuerman L. Anti-diphtheria antibody seroprotection rates are similar 10 years after vaccination with dTpa or DTPa using a mathematical model. Vaccine 23 (2004) 336-342
31. Pigeon J.G., Bohidar N.R., Zhang Z., and Wiens B.L. Statistical models for predicting the duration of vaccine-induced protection. Drug Inform J 33 (1999) 811-819
32. Renard D., Bruckers L., Molenberghs G., Vellinga A., and Van Damme P. Repeated-measures models to evaluate a hepatitis B vaccination programme. Stat Med 20 (2001) 951-963
33. Thiesen B., Greenwood B., Brieske N., and Achtman M. Persistence of antibodies to meningococcal IgA1 protease versus decay of antibodies to group A polysaccharide and Opc protein. Vaccine 15 (1997) 209-219